Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou

Similar documents
European Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai

Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco

Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia

Biotech / Life Science Sector

SWEDEN. Life Sciences Trend Analysis 2013

Swiss Biotechnology Venture Capital

Life Sciences Financing Summary EU August 2017

Partnering and Investment is the VC, Pharma, Biotech eco-system dead?

BIOTECH FINANCING SUMMARY October 2016

MARKET ENTRY SOLUTIONS IN THE WORLD S LARGEST ECONOMY

Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:

The European Medical Technology Industry. in figures / 2018

We are the right partner for

The Worldwide Alpha-1 Antitrypsin Market. Present Situation and Future Prospects

Globaldata. Publisher Sample

Our reports HEALTHCARE & LIFE SCIENCES REVIEW

SAMPLE. Bracco Imaging S.p.A.Market Share Analysis. Bracco Imaging S.p.A. Market Share Analysis GDME0639CDB / Published January 2013

HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS

What is One Nucleus? Vision. Mission

The European Medical Technology Industry in figures

QUESTIONNAIRE FOR FIRMS. INNOVATION-BASED STRATEGIES FOR GLOBALIZATION Questionnaire for SECTOR NAME (COUNTRY NAME)

Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011

CORPORATE PRESENTATION

Thailand Medical Industry Overview

Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems

Medical Sensors Market Research Report- Global Forecast to 2022

WORKFORCE METRICS BENCHMARK REPORT

GRI Sustainability Reporting Statistics Publication year By Report Services

Biotechnology Report. Latvia

L A B O R M A R K E T B R I E F I N G S S E R I E S

North America Surgical Sutures Market Outlook to 2020

rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

Supported by: Flanders Welcome Team Life Sciences

6-1 Copyright 2011 Pearson Education, Inc. publishing as Prentice Hall. PowerPoint by: Mohamad Sepehri, Ph.D. Jacksonville University

Microsoft Dynamics 365 Business Central. Licensing Guide - Simplified. May 2018

SAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014

The UK Life Sciences Industry and the Public Markets, 2016/17. World class science, world class investment opportunities

2009 Talent Shortage Survey Results

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research

CLINICAL TRIALS IN RUSSIA

Dedicated to Molecular Diagnostics

2009 Talent Shortage Survey Results

Welcoming and Introduction of SPECTARIS Facts and figures of an industry caring for our future health

BRIC Surgical Sutures Market Outlook to 2020

Energy & Climate Change ENYGF 2015

SAMPLE. North America Trauma Fixation Procedures Outlook to 2020

Fabrice BRECHET, Founder and Managing Director

Clinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013

Global Polyacrylamide (PAM) Market Study ( )

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

2015 REGIONAL SENIOR EXECUTIVE REWARD SURVEY MERCER EXECUTIVE REMUNERATION GUIDES (MERG) CHINA, HONG KONG, INDIA, JAPAN AND SINGAPORE

Biotechnology Report CROATIA

Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND LOMBARDY


Transparency Market Research. Buy Now. Request Sample. Published Date: June Single User License: US $ Multi User License: US $ 7595

Winsoft Solutions L.L.C

Jaana Korhonen, 3rd International Congress on Planted Forests Porto, Portugal May 18, 2013

ANALYTICAL STANDARDS AND REAGENTS

Impact of MRCT after ICH E17 fully implement -Industry perspective-

Clinical Laboratory Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,

Ausbiotech Biotech Invest Summit

Meat Marketing Strategy

GMP. Safeguard The Patient s Health.

China Biopsy Devices Market Outlook to 2020

United Kingdom Tissue Engineered - Skin Substitutes Market Outlook to 2020

New energy realities

Consulting Storage Software Services Training. NoCount

Brazil Gastric Balloon Procedures Outlook to 2020

World Potato Map 2019: Fries Are on the Menu Globally

HEALTH WEALTH CAREER MERCER COMPTRYX A NEW WAY FOR HR TO DELIVER BUSINESS INTELLIGENCE 17 NOVEMBER 2017 BY PATRICK GUTMANN MERCER

The Innovation Union Scoreboard: Monitoring the innovation performance of the 27 EU Member States

Solution Partner Program Global Perspective


NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program FUNDAMENTALS OF MEDICAL DEVICE REGULATORY AFFAIRS

Winsoft Solutions L.L.C

Outsourcing in Clinical Trials Europe 2014

Gazprom s export strategy to Europe: Ensuring security of supply vs challenges from US LNG where does Asia fit in and how high can exports go?

Introduction to Strategic Management

Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020

France Pressure Relief Devices Market Outlook to 2020

The Globalization of Biotechnology. Alicia Löffler Northwestern University

European Road Freight Transport 2012

The Swiss Medical Technology Industry 2018 Sector Study SMTI

The Cost of the Kyoto Protocol: Moving Forward on Climate Change Policy While Preserving Economic Growth

Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V

Annual Statistical Report on Procurement

Hannover, your first foothold for business expansion into Europe

European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013

100% #1 in the Eastern Europe since Clients suggest our services. >1000 clients. Client satisfaction average rating is constant 8,2

Biotechnology Certificate New Technologies For Health

Status of Bioenergy and roadmap to the future

Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success

This short guide aims to provide you with an introduction to BrandZ...

Japan Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020

Supply Demand Talent Shortage Survey Results

FACT SHEET. A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies.

What are the market failures in EU?

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1

Rotor-Gene Q quick-start guide

COMPANY UPDATE ASX / MEDIA RELEASE. The Manager Company Announcements Office ASX Limited

Transcription:

Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou 1

Overview 1. Overview European Medtech Venture Valuation: Independent assessment and valuation of technology driven companies / products in growth industries Biotechgate.com the Global Life Sciences Database Exclusive Partner in China: 2

European Medtech / Biotechgate Partners Source: Biotechgate.com 3

European Medtech Switzerland Germany UK France Sweden Reusable instruments 89 265 26 25 130 Electro mechanical medical devices 54 96 20 21 69 Single use devices 43 82 23 17 68 Non-active implantable devices 49 72 10 35 34 Dental devices 30 60 1 10 40 Technical aids for disabled persons 35 31 1 4 61 Imaging 19 48 16 16 27 Hospital hardware 35 40 6 7 34 Diagnostic devices 14 36 17 4 23 Other 211 494 115 115 331 Total Entries 579 1224 235 254 817 Total Medtech Companies 257 497 113 123 362 Total Medtech Companies: USA 1425 Europe 1857 Source: Biotechgate.com 4

Total Value in Million USD Number of Financing Rounds www.venturevaluation.com Industry Trends: 3. Financing 900 Medtech Financing Rounds Quarterly (US & EU) 60 800 700 50 600 40 500 400 30 300 20 200 100 10 0 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Financing Value EU ($) 33 32 11 101 52 59 123 50 50 54 Financing Value US ($) 638 547 345 272 619 568 653 278 606 503 No. of Rounds EU 25 11 6 11 15 12 10 7 9 6 No. of Rounds US 32 39 38 30 43 43 55 21 45 19 0 5

Industry Trends: 3. Financing Biotech Therapeutic Financing Rounds Quarterly 140 Switzerland France Germany United Kingdom Other 120 3 9 24 100 80 54 1 16 4 13 63 63 1 16 60 40 20 0 63 1 22 22 6 53 25 8 67 10 1 13 54 13 2 26 32 5 24 26 12 13 7 15 4 7 1 3 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 In million USD Source: Biotechgate.com 6

Industry Trends: 3. Financing Company name Amount m USD Ownership Country Date Pixium Vision S.A. 53.7 Public France 2014/06 invendo medical GmbH 28.1 Private Germany 2014/03 Sequana Medical AG 26.0 Private Switzerland 2014/04 Biotec Pharmacon ASA 13.0 Public Norway 2014/04 Nyxoah 11.0 Private Belgium 2014/05 JenaValve Technology 10.0 Private Germany 2014/04 EDAP TMS S.A. 9.3 Public France 2014/05 EBS Technologies GmbH 5.5 Private Germany 2014/04 7

Cluster Report 2013 Study on 6 European key clusters Finance, HQ, Biz environment Based on Biotechgate database Solid LS industry focusing on nutraceutical and cosmetics France 60% of French LS companies undertake in-house R&D. This is the highest proportion in Europe Medical Technology not main strength Germany Highest number of LS companies of any European country with focus on Medical Devices Largest number of global HQs of domestic LS Largest LS workforce in absolute numbers

Cluster Report 2013 Ireland Second largest LS workforce relative to the active population Attractive location for manufacturing for domestic and foreign LS companies Diverse LS industry with particular strength in Medical Devices and Biotechnology Netherlands Attractive to regional HQs of non-domestic LS companies for their R&D Strong LS clusters with large number of global HQs of domestic companies Switzerland Largest number of regional HQs Highest LS workforce relative to the active population Strong in R&D and large LS workforce United Kingdom Strength is rather Biotech than Medical devices

Swiss Medtech Sucess factors - Interesting for regional or global HQ (Medtronic / Nobel) - Watch industry => micromechanics and low power consumption => advantage for medical devices - Strong finance industry / family offices - Swiss made as quality label in healthcare - Small local market => forced to export and compete internationally 10

Thank you! Slides available for download: www.venturevaluation.com => Resource Center Tel.: +41 43 321 86 60 Fax: +41 43 321 86 61 p.frei@venturevaluation.com Venture Valuation Singapore / Switzerland www.venturevaluation.com 11

Valuation Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Biotechgate.com the Global Life Sciences Database Offices Employees Clients HQ: Zurich with representative offices in Europe, North America and Asia 20 people in Switzerland / UK / Canada / Singapore / India Pharma, Biotech and Investors such as Novartis Venture Fund, GSK, European Investment Bank, 4SC, Arpida/Evolva, Celtic Pharma Biotech Associations / Governments like Biocom, Medicon Valley, BioHouston SwedenBio, BIOTECanada, Maryland 12

Valuation Services Company Valuation: Crucial factors and value creating milestones for strategic development Assessment of the management, market, science, technology/products Detailed calculation of the company s financial value Used for equity financing by investors and companies Product Valuation: Gold standard rnpv valuation for Pre-clinical and clinical products Analysis of development costs and time lines Patient population, competing products, pricing and product life cycle Scenario and sensitivity analyses Analysis of the current value, and forecasts of the future value 13

Biotechgate 30 000 company profiles in over 70 countries, 37 000 products, 6 200 licensing opportunities 1) Company Directory 2) Deals Database with financial information 3) Investors database 14